priors.science/reviews/non-alcoholic-fatty-liver-disease

Non Alcoholic Fatty Liver Disease

The current evidence on 55 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

55claims tracked

1,100primary papers reviewed

30 May 2026latest evidence review

Weeklyre-scored against new papers

12 Established · 35 Likely · 8 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableResmetirom first approved non-alcoholic steatohepatitis therapyResmetiromEstablished91%20

StableFIB-4 detects advanced non-alcoholic fatty liver disease fibrosisDiagnosisEstablished89%20

StableTirzepatide 15mg non-alcoholic steatohepatitis resolution 62%IncretinsEstablished89%20

StableResmetirom 80mg non-alcoholic steatohepatitis resolution 25.9%ResmetiromEstablished88%20

StableFibrosis stage predicts non-alcoholic fatty liver disease mortalityStagingEstablished88%20

StableFXR agonists cause pruritus and low-density lipoprotein riseFXREstablished87%20

StableResmetirom 80mg improves fibrosis stageResmetiromEstablished87%20

StableTirzepatide fibrosis improvement 51%IncretinsEstablished86%20

StableSemaglutide 2.4mg non-alcoholic steatohepatitis resolution 62.9%SemaglutideEstablished86%20

StableObeticholic acid 25mg fibrosis improvement 23%FXREstablished85%20

StablePNPLA3 I148M is the top non-alcoholic fatty liver disease risk geneGeneticsEstablished85%20

StableSemaglutide 2.4mg fibrosis improvementSemaglutideEstablished85%20

StableFood and Drug Administration rejected obeticholic acid for non-alcoholic steatohepatitisFXRLikely82%20

StableFIB-4 below 1.3 rules out advanced fibrosisDiagnosisLikely81%20

StablePioglitazone causes 2-5 kg weight gainPioglitazoneLikely81%20

StableResmetirom reduces low-density lipoprotein cholesterolResmetiromLikely80%20

StableBariatric surgery non-alcoholic steatohepatitis resolution 84%SurgeryLikely80%20

StableCilofexor reduces liver fat in non-alcoholic steatohepatitisFXRLikely79%20

Stable7-10% weight loss resolves non-alcoholic steatohepatitisLifestyleLikely79%20

StableNon-alcoholic fatty liver disease affects 25% of global adultsStagingLikely79%20

StableSemaglutide 0.4mg non-alcoholic steatohepatitis resolution 59%SemaglutideLikely78%20

StableFIB-4 predicts cardiovascular events in non-alcoholic fatty liver diseaseStagingLikely78%20

StableSteatosis not an independent mortality predictorStagingLikely77%20

StablePioglitazone non-alcoholic steatohepatitis resolution 51% in type 2 diabetesPioglitazoneLikely76%20

StableEmpagliflozin reduces liver fat in non-alcoholic fatty liver diseaseSglt2Likely76%20

Stable10% weight loss predicts fibrosis regressionLifestyleLikely75%20

StablePNPLA3 GG genotype doubles non-alcoholic fatty liver disease cirrhosis riskGeneticsLikely74%20

StablePioglitazone benefits non-diabetic non-alcoholic steatohepatitisPioglitazoneLikely74%20

StableSemaglutide reduces liver fat in non-alcoholic fatty liver diseaseSemaglutideLikely74%20

StableMagnetic resonance elastography outperforms transient elastography for fibrosis stagingDiagnosisLikely73%20

StablePNPLA3 GG genotype and type 2 diabetes highest cirrhosis riskGeneticsLikely73%20

StableBariatric surgery reduces adverse liver outcomesSurgeryLikely73%20

StableBariatric surgery reduces major adverse cardiovascular event riskSurgeryLikely73%20

StableHSD17B13 allele attenuates PNPLA3 riskGeneticsLikely72%20

StablePioglitazone improves non-alcoholic steatohepatitis fibrosisPioglitazoneLikely72%20

StableSGLT2 inhibitors reduce alanine aminotransferase and FIB-4Sglt2Likely72%20

StableIpragliflozin improves non-alcoholic steatohepatitis fibrosisSglt2Likely72%20

StableDapagliflozin reduces hepatic steatosisSglt2Likely72%20

StableAdvanced fibrosis triples non-alcoholic fatty liver disease mortalityStagingLikely72%20

StableBariatric surgery improves non-alcoholic steatohepatitis fibrosisSurgeryLikely72%20

StableFibrosis persists in 47% after surgerySurgeryLikely72%20

StableFAST score identifies high-risk non-alcoholic steatohepatitisDiagnosisLikely70%20

StableFIB-4 above 2.67 predicts 4-fold cardiovascular riskDiagnosisLikely70%20

StableNIS4 panel detects at-risk non-alcoholic steatohepatitisDiagnosisLikely67%20

StableWeight loss mediates tirzepatide non-alcoholic steatohepatitis resolutionIncretinsLikely65%20

StableRosiglitazone lacks pioglitazone benefitPioglitazoneLikely65%20

StableGLP-1 receptor agonists reduce liver events in type 2 diabetesSemaglutideUncertain63%20

StablePolygenic score predicts hepatocellular carcinoma risk in non-alcoholic fatty liver diseaseGeneticsUncertain62%20

StableLifestyle non-alcoholic steatohepatitis resolution rate 16%LifestyleUncertain62%20

StableFasting and exercise reduce hepatic fatLifestyleUncertain60%20

StableTofogliflozin improves non-alcoholic fatty liver disease histologySglt2Uncertain60%20

StableTirzepatide lowers adverse liver eventsIncretinsUncertain58%20

StableBariatric surgery superior to GLP-1 receptor agonists in non-alcoholic steatohepatitisSurgeryUncertain57%20

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic